MannKind Corp. Stock
Price
Target price
€3.59
€3.59
0.330%
0.012
0.330%
€7.34
10.07.26 / Tradegate
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
MannKind Corp. Stock
MannKind Corp. gained 0.330% compared to yesterday.
The stock is an absolute favorite of our community with 28 Buy predictions and no Sell predictions.
As a result the target price of 7 € shows a very positive potential of 95.15% compared to the current price of 3.59 € for MannKind Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for MannKind Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of MannKind Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | 0.330% | -10.325% | 13.873% | 10.234% | -27.271% | 0.476% | -13.021% |
| Evolus Inc | -3.420% | 0.201% | 3.216% | -27.636% | 9.541% | -7.442% | -42.039% |
| Heron Therapeutics Inc. | -4.440% | 0.915% | 8.194% | -80.064% | -66.338% | -65.909% | -96.867% |
| Rhythm Pharmaceuticals | -5.000% | 1.010% | 31.579% | 69.492% | 6.952% | 604.225% | 509.756% |
Comments
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target raised by HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target lowered by Mizuho from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind won FDA approval for Afrezza in pediatric patients ages 6 and older, expanding its inhaled mealtime
Why MannKind Stock Tumbled on Thursday
MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest
